Trending Down-0.3400 (-4.9275%)
  • Bid / Lots
    5.0000/ 1
  • Ask / Lots
    7.5000/ 7
  • Open / Previous Close
    6.7000 / 6.9000
  • Day Range
    Low 6.2713
    High 7.6500
  • 52 Week Range
    Low 3.5022
    High 42.0000
  • Volume
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 6.9
09:32 ET11766.92
10:00 ET4506.95
10:18 ET5007.65
10:22 ET1007.3311
10:33 ET1377.18
10:38 ET20667.18
10:42 ET1007.05
10:44 ET22007.04
10:45 ET1007.175
10:49 ET1007.18
11:00 ET1247.13
11:02 ET17006.91
11:16 ET1007.13
11:18 ET1007.14
11:34 ET1006.9001
11:54 ET2007.0199
11:56 ET1006.99
12:03 ET1006.9001
12:06 ET4347.0198
12:32 ET1007.0227
12:39 ET8976.97
12:44 ET5006.9
12:51 ET3156.72
12:53 ET5026.51
12:57 ET1006.6
01:00 ET21566.4001
01:02 ET1006.485
01:04 ET3006.74
01:09 ET1006.61
01:36 ET9596.61
01:40 ET2966.5
01:42 ET61776.4
01:44 ET7006.54
01:49 ET5006.6237
01:51 ET9886.66
01:54 ET1006.74
01:56 ET6006.763
02:02 ET1006.87
02:16 ET44806.8104
02:18 ET15326.65
02:21 ET7006.65
02:23 ET1006.77
02:25 ET6006.61
02:27 ET11006.7
02:32 ET15006.59
02:36 ET4006.6192
02:38 ET9526.66
02:39 ET21006.44
02:41 ET6006.48
03:01 ET2486.54
03:17 ET1036.445
03:35 ET4316.35
03:42 ET1006.33
03:46 ET3496.3299
03:50 ET6906.2713
03:51 ET1006.32
03:53 ET10596.41
04:00 ET3006.56
Data delayed at least 15 minutes.
No documents available
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesKTRA
Kintara Therapeutics Inc
United StatesONCR
Oncorus Inc
United StatesCING
Cingulate Inc
United StatesIPIX
Innovation Pharmaceuticals Inc
United StatesCNTB
Connect Biopharma Holdings Ltd
United StatesPHGE
Biomx Inc
As of 2023-01-29

Company Information

Kintara Therapeutics, Inc. is a clinical-stage, biopharmaceutical company focused on the development and commercialization of new cancer therapies. The Company is developing and commercializing anti-cancer therapies for patients whose solid tumors exhibit features that make them resistant to, or unlikely to respond to available therapies, with particular focus on orphan cancer indications. The Company’s two lead candidates include VAL-083 and REM-001. Its VAL-083 is a novel, validated, deoxyribonucleic acid (DNA) targeting agent, for the treatment of drug-resistant solid tumors such as glioblastoma multiforme (GBM) and potentially other solid tumors, including ovarian cancer, non-small cell lung cancer (NSCLC), and diffuse intrinsic pontine glioma (DIPG) The Company’s REM-001, a late-stage photodynamic therapy (PDT) for the treatment of cutaneous metastatic breast cancer (CMBC); basal cell carcinoma nevus syndrome (BCCNS), and access graft failure in hemodialysis patients.

Contact Information

9920 Pacific Heights Blvd Suite 150, Suite 200SAN DIEGO, CA, United States 92121


Chairman of the Board, President, Chief Executive Officer
Robert Hoffman
Chief Financial Officer
Scott Praill
Senior Vice President, Business Development
John Liatos
Chief Scientific Officer
Dennis Brown
Vice President - Research & Development
Steven Rychnovsky

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
Revenue (TTM)
Shares Outstanding
Dividend Yield
Annual Dividend Rate
Ex-Dividend Date
Pay Date
Book Value
P/E Ratio
Price/Sales (TTM)
Price/Cash Flow (TTM)
Operating Margin
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.